May 15, 2018 / 3:54 PM / in 7 months

BRIEF-U.S. FDA Approves Retacrit As Biosimilar To Epogen/Procrit For Treatment Of Anemia

May 15 (Reuters) - The U.S. Food and Drug Administration:

* SAYS APPROVED RETACRIT AS BIOSIMILAR TO EPOGEN/PROCRIT FOR TREATMENT OF ANEMIA

* SAYS GRANTED APPROVAL OF RETACRIT TO HOSPIRA INC, A PFIZER COMPANY

* SAYS AS WITH EPOGEN/PROCRIT, RETACRIT CONTAINS BOXED WARNING ABOUT INCREASED RISKS OF DEATH, HEART PROBLEMS, STROKE, TUMOR GROWTH OR RECURRENCE

* SAYS APPROVAL OF RETACRIT FOR TREATMENT OF ANEMIA CAUSED BY CHRONIC KIDNEY DISEASE, CHEMOTHERAPY, OR USE OF ZIDOVUDINE IN PATIENTS WITH HIV INFECTION

* SAYS RETACRIT HAS BEEN APPROVED AS A BIOSIMILAR, NOT AS AN INTERCHANGEABLE PRODUCT Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below